​

Zura Bio Stock (NASDAQ:ZURA)

ForecastOwnershipFinancialsChart
Zura Bio by TradingView

Previous Close

$3.55

52W Range

$1.00 - $7.44

50D Avg

$4.86

200D Avg

$4.60

Market Cap

$232.78M

Avg Vol (3M)

$732.38K

Beta

0.03

Div Yield

-

ZURA Company Profile

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

30

IPO Date

Mar 21, 2023

Website

ZURA Performance

ZURA Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-75.25M$-55.19M$-62.64M
Net Income$-99.35M$-52.40M$-60.36M
EBITDA$-75.25M$-55.18M$-62.64M
Basic EPS$-1.06$-0.60$-2.09
Diluted EPS$-1.06$-0.60$-2.09

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
AARDAardvark Therapeutics, Inc. Common Stock
FHTXFoghorn Therapeutics Inc.
ARCTArcturus Therapeutics Holdings Inc.
PYXSPyxis Oncology, Inc.
ENTAEnanta Pharmaceuticals, Inc.
TNYATenaya Therapeutics, Inc.
ASMBAssembly Biosciences, Inc.
NAUTNautilus Biotechnology, Inc.
SGMTSagimet Biosciences Inc.
IMRXImmuneering Corporation